Abstract Response Evaluation Criteria in Solid Tumors (RECIST) is the gold standard for
assessment of treatment response in solid tumors. Morphologic change of tumor size …

Response evaluation criteria in solid tumours (RECIST) v1. 1 are currently the reference
standard for evaluating efficacy of therapies in patients with solid tumours who are included …

The number of patients with primary cutaneous lymphoma (PCL) relative to other non-
Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical …

Abstract Background “Head Start” III, was a prospective clinical trial using intensive induction
followed by myeloablative chemotherapy and autologous hematopoietic cell rescue …

Data-driven science and its corollaries in machine learning and the wider field of artificial
intelligence have the potential to drive important changes in medicine. However, medicine is …

Mechanisms of therapeutic resistance and vulnerability evolve in metastatic cancers as
tumor cells and extrinsic microenvironmental influences change during treatment. To …

Purpose To analyze the frequency of discrepant interpretations of progressive disease (PD)
between routine clinical and formal Response Evaluation Criteria in Solid Tumors (RECIST) …

Objective. Patients with metastatic disease are followed throughout treatment with medical
imaging, and accurately assessing changes of individual lesions is critical to properly inform …

Optimal management of cancer patients relies heavily on late-phase oncology randomized
controlled trials. A comprehensive understanding of the key considerations in designing and …

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a need for better tools to
guide treatment selection and follow‐up. The aim of this prospective study was to investigate …